Discover Antibiotic Stewardship

Together, we can change the course of antibiotic resistance

The threat of drug-resistant bacteria continues to grow — and so does our commitment  to helping you combat this global issue. As a leader in diagnostics for more than 50 years, we have made it our mission to innovate and advocate for better antibiotic stewardship. 

Discover how Roche can help you bring insights and innovative solutions to your institution’s antibiotic stewardship program.

alt

*AMR mortality projection compared to leading causes of death worldwide in 2014

alt
It’s already putting lives in danger across the United States.

Antibiotics are an important treatment option, but their misuse is causing devastating impact.

alt
alt

cobas® Liat® PCR System

Treat common infections with confidence at the earliest possible convenience.

Accuracy and speed that 
support antibiotic stewardship
 

This CLIA-waived system is uniquely positioned to provide accurate, actionable results at the point of care. Whether results are positive or negative, you can confidently treat patients without the need to wait for confirmation.

 

✓ Influenza A/B
✓ RSV
✓ Group A Strep
alt
alt
Help determine if antibiotics are needed or if certain bacterial infections are resolving.
 

The Elecsys BRAHMS PCT solution aids in assessing the mortality risk of patients fighting sepsis and guiding antibiotic decision-making for patients with lower respiratory tract infections, like pneumonia, bronchitis, COPD and sepsis.8,9

alt

cobas® MRSA/SA
and Cdiff Tests

Identify and contain healthcare-associated infections (HAIs).

Timely and cost-effective molecular solutions for improved HAI management
 

The cobas MRSA/SA and Cdiff tests provide provide excellent performance and broad coverage to increase confidence in HAI testing. Run on the fully automated cobas 4800 system, these assays may help your institution control infections and costs.

 

✓ Decrease transmission
✓ Reduce antibiotic use over time
alt
alt
Let’s help stop antibiotic resistance together.

Roche is your partner in building a successful antibiotic stewardship program that’s designed to:

alt
alt
alt
Who's driving antibiotic stewardship?
SHEA-logo
Bring innovative solutions to your institution.
CONTACT US

References

1 The Review on Antimicrobial Resistance. “Tackling Drug-Resistant Infections Globally: Final Report and Recommendations.” May 2016, https://amr-review.org/sites/default/files/160525_Final%20paper_with%20cover.pdf (accessed September 25, 2017).

2 Centers for Disease Control and Prevention. “1 in 3 antibiotic prescriptions unnecessary.” CDC Newsroom. https://www.cdc.gov/media/releases/2016/p0503-unnecessary-prescriptions.html (accessed February 6, 2018).

3 Centers for Disease Control and Prevention. “The Core Elements of Hospital Antibiotic Stewardship Programs.” https://www.cdc.gov/antibiotic-use/healthcare/implementation/core-elements.html (accessed February 6, 2018).

4 Magill SS, O'Leary E, Janelle SJ, et al. Changes in Prevalence of Health Care–Associated Infections in U.S. Hospitals. N Engl J Med 2018; 379:1732-1744. https://www.nejm.org/doi/full/10.1056/NEJMoa1801550. Accessed November 12, 2018..

5 National Quality Forum. “National Quality Partners Playbook: Antibiotic Stewardship in Acute Care.” http://www.qualityforum.org/Publications/2016/05/National_Quality_Partners_Playbook__Antibiotic_Stewardship_in_Acute_Care.aspx (accessed February 6, 2018).

6 Hansen, Glen T., Johanna Moore, Emily Herding, Tami Gooch, Diane Hirigoyen, Kevan Hanson and Marcia Deike. (2018). Clinical decision making in the emergency department setting using rapid PCR: Results of the CLADE study group. Journal of Clinical Virology 102:42–49.

7 Peppard, W.J. and N.A. Ledeboer. (2014). Implementation of Polymerase Chain Reaction to Rule Out Clostridium Difficile Infection is Associated with Reduced Empiric Antibiotic Duration of Therapy. Hospital Pharmacy 49(7):639–643.

8 Elecsys BRAHMS PCT [package insert]. Indianapolis, IN: Roche Diagnostics; 2016.

9 Elecsys BRAHMS PCT antibiotic initiation and deescalation claims are pending 510(k) clearance.

10 Broyles, Michael R. (October 3, 2017). “Impact of Procalcitonin-Guided Antibiotic Management on Antibiotic Exposure and Outcomes: Real-world Evidence.” Open Forum Infectious Diseases. Volume 4, Issue 4, ofx213. https://doi.org/10.1093/ofid/ofx213 (accessed July 24, 2018).

COBAS, LIAT and ELECSYS are trademarks of Roche.

© 2018 Roche Diagnostics, North America. All rights reserved.